These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32876863)

  • 21. Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis.
    Yoon JH; Min SH; Ahn CH; Cho YM; Hahn S
    Sci Rep; 2018 Mar; 8(1):4095. PubMed ID: 29511288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interventions for people with type 2 diabetes mellitus fasting during Ramadan.
    Lee SWH; Chen WS; Sellappans R; Md Sharif SB; Metzendorf MI; Lai NM
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013178. PubMed ID: 37435938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
    Chai S; Zhang R; Zhang Y; Carr RD; Zheng Y; Rajpathak S; Ji L
    Front Endocrinol (Lausanne); 2022; 13():994944. PubMed ID: 36313782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.
    Chen Y; Men K; Li XF; Li J; Liu M; Fan ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3502-3514. PubMed ID: 29917205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
    De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
    Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
    Sahay RK; Giri R; Shembalkar JV; Gupta SK; Mohan B; Kurmi P; Kumar SR; Sawardekar VM; Mishra A; Murthy LS; Arya VV; Sonawane AR; Soni PN; Gofne SK; Karnawat SR; Rajurkar MN; Patel PM; Lakhwani LK; Mehta SC; Joglekar SJ
    Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.
    Yu M; Yang Z; Chen C; Lv Y; Xiang L; Zhao S; Li R
    Diabetol Metab Syndr; 2022 Oct; 14(1):153. PubMed ID: 36271423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Chai S; Zhang R; Zhang Y; Carr RD; Zheng Y; Rajpathak S; Yu M
    Front Endocrinol (Lausanne); 2022; 13():935039. PubMed ID: 36017316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
    Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
    Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
    Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P; Wojciechowski P; Siejka S; Małecki P; Hak L; Malecki MT
    Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.
    Ling J; Cheng P; Ge L; Zhang DH; Shi AC; Tian JH; Chen YJ; Li XX; Zhang JY; Yang KH
    Acta Diabetol; 2019 Mar; 56(3):249-272. PubMed ID: 30242726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: A meta-analysis.
    Zhou X; Shi H; Zhu S; Wang H; Sun S
    J Diabetes Investig; 2022 Mar; 13(3):468-477. PubMed ID: 34551206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
    Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
    JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
    Zhao M; Chen J; Yuan Y; Zou Z; Lai X; Rahmani DM; Wang F; Xi Y; Huang Q; Bu S
    Sci Rep; 2017 Aug; 7(1):8273. PubMed ID: 28811622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: a single-arm study, a brief report.
    Okura T; Fujioka Y; Nakamura R; Ito Y; Kitao S; Anno M; Matsumoto K; Shoji K; Okura H; Matsuzawa K; Izawa S; Ueta E; Kato M; Imamura T; Taniguchi SI; Yamamoto K
    Diabetol Metab Syndr; 2022 Jun; 14(1):78. PubMed ID: 35672759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.